Eli Lilly
Signals mentioning Eli Lilly
- Mounjaro overtakes legacy medicines to become India’s top-selling drug
- India’s GLP-1 market stabilises as generic semaglutide boom fades
- Tata Consumer readies nutrition products for India’s GLP-1 weight-loss drug users
- Cipla prioritises Yurpeak as sales nearly double, delaying semaglutide launch
- Cipla’s India sales rise 12% as it leans on consumer-health expansion
- Cipla Q1FY27 profit falls 39% despite record India sales
- Pharma-nutrition tie-ups race to capture $150B GLP-1 companion market
- Semaglutide channel chokes on Rs 100cr excess stock as April generic rush fades
- DCGI orders nationwide crackdown on illegal sildenafil, tadalafil sales across pharmacies and e-platforms